1  and stroke in men treated with PDE5i versus alprostadil.

2 en treated with PDE5i and 1,994 treated with alprostadil.

3  home treatment; 299 of the 461 treated with alprostadil (64.9 percent) had intercourse successfully

4  association between treatment with PDE5i or alprostadil and outcomes in men with stable coronary art

5 racavernosal injections of the prostaglandin alprostadil are effective for treating erectile dysfunct

6 I or revascularization who received PDE5i or alprostadil during 2006 through 2013 at >6 months after

7   We investigated the efficacy and safety of alprostadil formulated for intracavernosal treatment in

8 gher response rates with increasing doses of alprostadil (from 2.5 to 20 microg).

9 14%) in the PDE5i group and 521 (26%) in the alprostadil group.

10 le dysfunction, intracavernosal injection of alprostadil is an effective therapy with tolerable side

11  treatment with either the effective dose of alprostadil or placebo for three months at home.

12               Rationale: Prostaglandin E(1) (alprostadil; PGE(1)), in addition to low-dose unfraction

13               We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethra

14                          PDE5i compared with alprostadil treatment was associated with lower mortalit

15 failure, and revascularization compared with alprostadil treatment.

16                                        Among alprostadil users, those in q5 had a lower all-cause mor

17                                              Alprostadil was delivered transurethrally in a double-bl

18 dose-response study of 296 men, all doses of alprostadil were superior to placebo and there was a sig